Epizyme Inc.’s new chief executive Robert Bazemore understands the disease his company is targeting only too well. When he was introduced to employees this summer, Bazemore surprised them by disclosing that he’s a survivor of non-Hodgkin’s lymphoma, a life-threatening blood cancer that could potentially be treated by the company’s lead drug candidate.
https://www.passle.net/Content/Images/passle_logo-186px.png Passle https://passle.net
More posts by Park Square Executive Search
Recent posts from Park Square Executive Search
As a free user, you can follow Passle and like posts.
To repost this post to your own Passle blog, you will need to upgrade your account.
For plans and pricing, please contact our sales team at firstname.lastname@example.org